Percutaneous Ethibloc injection in the treatment of primary aneurysmal bone cysts.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16093949.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The effects of percutaneous Ethibloc (Ethicon/Johnson & Johnson, St-Stevens-Woluwe, Belgium) injection into primary aneurysmal bone cysts were analysed. Two patients with a venous drainage after injection of a medium contrast were excluded. Twelve patients underwent at least one percutaneous injection of Ethibloc. The average follow-up period was 5.1 years. At final follow-up, six patients had complete healing of the cyst, three had partial healing and three, who had no response, were treated by curettage and bone grafting. Complete healing was observed for all the aggressive lesions. No major complications were noted. Ethibloc injection may be performed as a primary treatment of aneurysmal bone cysts if the technique is followed with precision.
Medical subject headings
- Bone Cysts, Aneurysmal
- Diatrizoate
- Fatty Acids
- Propylene Glycols
- Sclerosing Solutions
- Zein